Eli Lilly
LLY
Eli Lilly (LLY) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $8.38
- EPS estimate
- $6.01
- EPS surprise
- +39.52%
- Revenue surprise
- +11.07%
- Revenue
- $23.0B
- Revenue estimate
- $20.7B
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $6.01 | $8.38 | +39.52% | $23.0B | SEC |
| Q1 2026 | Apr 30, 2026 | $6.97 | $8.55 | +22.71% | $19.8B | SEC |
| Q4 2025 | Feb 4, 2026 | $6.91 | $7.54 | +9.10% | $19.3B | SEC |
| Q3 2025 | Oct 30, 2025 | $5.69 | $7.02 | +23.33% | $17.6B | SEC |
| Q2 2025 | Aug 7, 2025 | $5.60 | $6.31 | +12.70% | $15.6B | SEC |
| Q1 2025 | May 1, 2025 | $3.26 | $3.34 | +2.51% | $12.7B | SEC |
| Q4 2024 | Feb 6, 2025 | $5.04 | $5.32 | +5.45% | $13.5B | SEC |
| Q3 2024 | Oct 30, 2024 | $1.42 | $1.18 | −16.97% | $11.4B | SEC |
| Q2 2024 | Aug 8, 2024 | $2.74 | $3.92 | +42.93% | $11.3B | SEC |
| Q1 2024 | Apr 30, 2024 | $2.47 | $2.58 | +4.64% | $8.8B | SEC |
| Q4 2023 | Feb 6, 2024 | $2.30 | $2.49 | +8.45% | $9.4B | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.18 | $0.10 | +155.90% | $9.5B | SEC |
| Q2 2023 | Aug 8, 2023 | $1.98 | $2.11 | +6.61% | $8.3B | SEC |
| Q1 2023 | Apr 27, 2023 | $1.73 | $1.62 | −6.13% | $7.0B | SEC |
| Q4 2022 | Feb 2, 2023 | $1.78 | $2.09 | +17.22% | $7.3B | SEC |
| Q3 2022 | Nov 1, 2022 | $1.91 | $1.98 | +3.44% | $6.9B | SEC |
| Q2 2022 | Aug 4, 2022 | $1.70 | $1.25 | −26.48% | $6.5B | SEC |
| Q1 2022 | Apr 28, 2022 | $2.29 | $2.62 | +14.30% | $7.8B | SEC |
| Q4 2021 | Feb 3, 2022 | $2.45 | $2.49 | +1.79% | $8.0B | SEC |
| Q3 2021 | Oct 26, 2021 | $1.96 | $1.94 | −1.16% | $6.8B | SEC |
Quarterly revenue
Frequently asked questions
When did Eli Lilly (LLY) last report earnings?
Eli Lilly last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did LLY beat earnings estimates?
Yes. Eli Lilly reported EPS of $8.38 for Q2 2026 against a $6.01 estimate — a 39.52% beat.
How much revenue did LLY report last quarter?
Eli Lilly reported $23.0B in revenue for Q2 2026, against a consensus estimate of $20.7B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.